Login to Your Account

GLAAS half-full in synovial sarcoma

$80M verdict on CMB-305: Immune Design's phase III gets validated in fine form

By Randy Osborne
Staff Writer

Thursday, October 26, 2017

A degree of investor fretting over Immune Design Corp.'s interaction with the FDA on the subject of phase III plans with CMB-305 in synovial sarcoma didn't stop the Seattle-based firm from pricing a public offering of 19.5 million shares at $4.10 each.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription